StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Wednesday morning. The firm issued a hold rating on the stock.

Other research analysts have also issued reports about the stock. HC Wainwright reiterated a buy rating and issued a $5.00 target price on shares of DBV Technologies in a research report on Thursday, August 1st. JMP Securities upped their target price on shares of DBV Technologies from $4.00 to $5.00 and gave the stock a market outperform rating in a research report on Wednesday, July 31st.

DBV Technologies Price Performance

DBVT opened at $0.76 on Wednesday. The company has a fifty day moving average price of $0.88 and a 200-day moving average price of $1.14. The firm has a market capitalization of $73.55 million, a P/E ratio of -0.91 and a beta of 0.68. DBV Technologies has a one year low of $0.50 and a one year high of $3.02.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. The firm had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $1.42 million. During the same quarter last year, the firm earned ($0.26) earnings per share. On average, analysts expect that DBV Technologies will post -1.43 earnings per share for the current year.

Institutional Trading of DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Cowen AND Company LLC purchased a new position in DBV Technologies S.A. (NASDAQ:DBVT) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 50,986 shares of the company’s stock, valued at approximately $49,000. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.